AI-powered intelligent medication risk monitoring system based on wearable device vital sign data collection
By combining smartwatches and cloud-based AI analytics platforms, drug risks can be monitored and identified in real time, addressing the shortcomings of existing technologies in drug safety monitoring and enabling safe drug use and personalized management throughout the entire process.
Patent Information
- Application Number
- CN202611475757.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-21
- Publication Date
- 2026-11-17
AI Technical Summary
Existing smartwatches and mobile health apps cannot achieve full-process safety monitoring of medication in daily medication use scenarios for chronic diseases. They cannot link drug side effects with real-time vital signs and exercise data, lack AI-based mechanisms for automatically identifying drug interactions, lack logic for verifying the authenticity of medication use and making reverse judgments on drug efficacy, and their medication management is fragmented.
The AI-powered intelligent medication risk monitoring system, which uses smart wearable devices to collect vital signs data, compares the collected data with the threshold values of lightweight drugs to identify risk events; the cloud-based AI analysis platform performs drug interaction simulations to generate personalized medication plans; and the mobile APP terminal synchronizes medication records and risk events.
It enables full-process safety monitoring of medication, reduces the probability of adverse drug reactions, provides personalized medication advice, solves the problems of missed doses and false medication use in chronic diseases, and supports full-cycle traceability of medication data.
Smart Images

Figure CN123120323A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of intelligent medical monitoring technology, and in particular to an AI-powered intelligent medication risk monitoring system based on intelligent wearable device vital sign collection. Background Technology
[0002] Drug therapy is a fundamental means of clinical disease intervention, but medication risks remain a core challenge in the field of medical safety. In the daily medication use scenarios for chronic diseases, existing smartwatches and mobile health apps only provide basic medication alarm reminders, which are limited in function and have many technical deficiencies, failing to achieve safe monitoring throughout the entire medication process. Summary of the Invention
[0003] In view of this, the purpose of this invention is to provide an AI-based intelligent medication risk monitoring system based on smart wearable device vital sign collection, so as to realize the safety monitoring of the entire medication process and improve medication safety.
[0004] To achieve the above objectives, the technical solution adopted by the present invention is as follows: In a first aspect, the present invention provides an AI-powered intelligent medication risk monitoring system based on wearable device-based vital sign data collection, comprising: a smartwatch terminal for collecting real-time vital sign data and movement status of users, comparing the real-time vital sign data and movement status with pre-set lightweight drug thresholds, and identifying risk events based on the comparison results; a mobile APP terminal for receiving and synchronizing medication records, risk events, and vital sign data uploaded by the smartwatch terminal; and a cloud-based AI analysis platform for storing a pharmaceutical knowledge base and performing drug interaction simulations based on the pharmaceutical knowledge base.
[0005] Optionally, the smartwatch terminal has a built-in lightweight drug threshold library, which includes: the medication window period and lightweight drug thresholds for each drug; among which, the lightweight drug thresholds include: contraindication thresholds and efficacy improvement thresholds; the smartwatch terminal is used for parallel background monitoring of multiple drugs, and the medication window period, preset efficacy monitoring duration after medication, contraindication thresholds and efficacy improvement thresholds for each drug are configured independently and do not interfere with each other.
[0006] Optionally, during the medication window, the smartwatch terminal is used to compare the currently collected vital sign data with the contraindication threshold of the drug in real time. If the currently collected vital sign data exceeds the contraindication threshold, a local risk warning is triggered. During the preset efficacy monitoring period after medication, the smartwatch terminal is used to compare the changing trend of vital sign data with the efficacy improvement threshold of the drug. If the changing trend of vital sign data does not reach the efficacy improvement threshold, an abnormal efficacy warning is triggered and the medication behavior is reconfirmed through a pop-up window.
[0007] Optionally, a cloud-based AI analysis platform is used to retrieve medical knowledge bases based on all medications used and daily dietary records entered by the user to perform multi-drug combination and drug-food interaction simulations, output graded and visualized risk alerts, and generate periodic medication safety reports.
[0008] Optionally, the smartwatch terminal includes: a heart rate sensor, a blood pressure monitoring module, a motion posture sensor, a sleep monitoring module, and a local storage unit; the heart rate sensor, blood pressure monitoring module, motion posture sensor, and sleep monitoring module are used to collect the user's heart rate, blood pressure, exercise status, and sleep data, respectively, and cache the collected data to the local storage unit.
[0009] Optionally, the cloud-based AI analytics platform can also be used to generate personalized optimization plans based on users' historical heart rate and sleep data. These personalized optimization plans include recommendations for alternative medications, suggestions for adjusting medication administration times, and guidelines for rest and recuperation.
[0010] Optionally, the smartwatch terminal includes: a drug parameter setting module, used to configure the user's medication time, dosage, precautions, as well as the medication window period, contraindication threshold, efficacy monitoring duration, efficacy threshold, and risk warning parameters for each drug.
[0011] Secondly, the present invention provides an AI-based intelligent medication risk monitoring method based on intelligent wearable vital sign data collection, applicable to any of the AI-based intelligent medication risk monitoring systems provided in the first aspect above. The method includes: collecting real-time vital sign data and movement status of users through a smartwatch terminal, comparing the real-time vital sign data and movement status with a pre-set lightweight drug threshold, and identifying risk events based on the comparison results; receiving and synchronizing medication records, risk events, and vital sign data uploaded by the smartwatch terminal through a mobile APP terminal; and storing a medical knowledge base through a cloud-based AI analysis platform and performing drug interaction deduction based on the medical knowledge base.
[0012] Thirdly, the present invention provides an electronic device including a processor and a memory, the memory storing computer-executable instructions executable by the processor, the processor executing the computer-executable instructions to implement the steps of the method provided in any of the first aspects above.
[0013] Fourthly, the present invention provides a computer-readable storage medium storing a computer program, wherein the computer program, when executed by a processor, performs the steps of the method provided in any of the first aspects above.
[0014] This invention brings the following beneficial effects: The AI-powered intelligent medication risk monitoring system based on wearable device-based vital sign data collection provided by this invention includes: a smartwatch terminal for collecting real-time vital sign data and movement status of users, comparing the real-time vital sign data and movement status with pre-set lightweight drug thresholds, and identifying risk events based on the comparison results; a mobile APP terminal for receiving and synchronizing medication records, risk events, and vital sign data uploaded by the smartwatch terminal; and a cloud-based AI analysis platform for storing a medical knowledge base and performing drug interaction simulations based on the medical knowledge base. In this system, the smartwatch terminal collects real-time vital sign data and movement status of users and compares it with pre-set lightweight drug thresholds to identify risk events. Simultaneously, the cloud-based AI analysis platform performs drug interaction simulations based on the medical knowledge base, enabling real-time interception of health risks caused by post-medication activities such as exercise and dietary changes, reducing the probability of adverse drug reactions, and improving medication safety. Furthermore, the mobile APP terminal can receive and synchronize medication records, risk events, and vital sign data uploaded by the smartwatch terminal, thereby achieving full-process safety monitoring of medication use.
[0015] Other features and advantages of the invention will be set forth in the description which follows, and will be apparent in part from the description, or may be learned by practicing the invention. The objects and other advantages of the invention are realized and obtained in accordance with the structures particularly pointed out in the description, claims and drawings.
[0016] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, preferred embodiments are described below in detail with reference to the accompanying drawings. Attached Figure Description
[0017] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.
[0018] Figure 1 This is a schematic diagram of the structure of an AI-powered intelligent medication risk monitoring system based on intelligent wearable vital sign collection, provided in an embodiment of the present invention. Figure 2 This is a schematic diagram of a watch application list provided in an embodiment of the present invention; Figure 3 This is a schematic diagram of a smart drug efficacy monitoring details page provided in an embodiment of the present invention; Figure 4 This is a schematic diagram of a graded risk warning page provided in an embodiment of the present invention; Figure 5This is a schematic diagram of a drug classification page provided in an embodiment of the present invention; Figure 6 This is a schematic diagram of a drug category details page provided in an embodiment of the present invention; Figure 7 This is a schematic diagram of a drug parameter setting page provided in an embodiment of the present invention; Figure 8 This is a schematic diagram of a first-level page of a watch dial provided in an embodiment of the present invention; Figure 9 This is a schematic diagram of a daily medication statistics panel provided in an embodiment of the present invention; Figure 10 This is a schematic diagram of a single-category drug details page provided in an embodiment of the present invention; Figure 11 This is a schematic diagram of a smart medication monitoring page on a mobile app, provided as an embodiment of the present invention. Figure 12 This is a schematic diagram of a newly added drug page provided in an embodiment of the present invention; Figure 13 This is a schematic diagram of AI drug action analysis provided in an embodiment of the present invention; Figure 14 This is a schematic diagram of a monthly medication safety report provided in an embodiment of the present invention; Figure 15 A schematic diagram of a system architecture provided for an embodiment of the present invention; Figure 16 This is a flowchart illustrating an AI-powered intelligent medication risk monitoring method based on smart wearable device vital sign collection, provided in an embodiment of the present invention. Figure 17 This is a schematic diagram of the structure of an electronic device provided in an embodiment of the present invention. Detailed Implementation
[0019] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0020] Currently, in the context of routine medication use for chronic diseases, existing smartwatches and mobile health apps only provide basic medication alarm reminders, which are limited in function and have several technical shortcomings: (1) Unable to link drug side effects with real-time vital signs and exercise data: Only static display of drug instructions, unable to identify high-risk scenarios such as strenuous exercise or excessive heart rate during the medication window, and unable to proactively push side effect risk warnings; (2) No AI-based automatic identification of drug interaction mechanisms: Users need to manually query drug contraindications, cannot automatically match multiple drugs, and lack a visual risk classification interface; (3) Lack of medication authenticity verification and reverse judgment logic: relying on users to manually confirm medication, it cannot recognize accidental cancellation by alarm clock or missed dose; when blood pressure, heart rate and other vital signs do not improve after medication, the system has no automatic warning mechanism. (4) Fragmented medication management: only one reminder, no ability to track treatment courses, missed doses, or review long-term medication use.
[0021] Based on this, the present invention provides an AI-powered intelligent medication risk monitoring system based on intelligent wearable vital sign collection, which can realize full-process safety monitoring of medication and improve medication safety.
[0022] To facilitate understanding of this embodiment, we will first describe the AI-powered intelligent medication risk monitoring system based on smart wearable device vital sign collection disclosed in this embodiment of the invention. (See also...) Figure 1 The diagram shown illustrates the structure of an AI-powered intelligent medication risk monitoring system based on wearable device vital sign data collection. It shows that the system mainly includes: The smartwatch terminal 10 is used to collect the user's real-time vital signs data and movement status, and compare the real-time vital signs data and movement status with the pre-set lightweight drug threshold, and identify risk events based on the comparison results.
[0023] See Figure 2 As shown, select the "Smart Medication Monitoring" function from the application list on the smartwatch terminal 10 and click to enter the medication homepage. The medication homepage displays the added frequently used medicine cards by default. The medicine cards include: medicine icon, preset medication time period, medication dosage, and medication reminder; the reminder area of the card during the medication window period is displayed solidly to distinguish it from medicines outside the window period; a "Medication Management" icon is set at the bottom of the medication homepage, clicking which will jump to the five major medicine category pages: Western medicine for chronic diseases, traditional Chinese medicine, dietary supplements, temporary emergency medicines, and other medicines; the medication homepage is arranged in ascending order according to the daily medication time set by the user, and newly added medicines are uniformly arranged at the end of the list.
[0024] In one implementation, the smartwatch terminal 10 supports parallel background monitoring of multiple medications, simultaneously collecting heart rate, exercise data, and blood pressure, and performing risk assessments for multiple medications in parallel. Specifically, the smartwatch terminal 10 includes: a heart rate sensor, a blood pressure monitoring module, a motion posture sensor, a sleep monitoring module, and a local storage unit; the heart rate sensor, blood pressure monitoring module, motion posture sensor, and sleep monitoring module are used to collect the user's heart rate, blood pressure, exercise status, and sleep data, respectively, and cache the collected data to the local storage unit.
[0025] See Figure 3 As shown, after selecting the corresponding drug card, clicking on "Smart Medication Monitoring" will take you to the Smart Drug Efficacy Monitoring Details Page, which includes: Medication Monitoring Startup Page: Real-time display of medication time, dosage and precautions, monitoring time, and current vital signs data; among which, the current vital signs data includes heart rate, blood pressure, body temperature, and exercise status recognition results (resting / slow walking / strenuous exercise); The medication monitoring feature includes a switch; clicking it will terminate the monitoring of the medication. The medication monitoring supports continuous background monitoring, with a risk status icon permanently displayed on the main dial of the smartwatch terminal 10. Clicking the icon will quickly take you to the intelligent drug efficacy monitoring. The local AI pre-stores lightweight drug thresholds, and the background compares and analyzes these thresholds with current vital signs and exercise data in real time to identify risk events.
[0026] In practical implementation, the smartwatch terminal 10 has a built-in lightweight drug threshold library, which includes: the medication window period (which can be understood as the medication cycle set by the user) and lightweight drug thresholds for each drug; among which, the lightweight drug thresholds include: contraindication thresholds and efficacy improvement thresholds; the smartwatch terminal 10 supports parallel background monitoring of multiple drugs, and the medication window period, preset efficacy monitoring duration after medication, contraindication thresholds and efficacy improvement thresholds for each drug are configured independently and do not interfere with each other.
[0027] Based on this, during the medication window period, the smartwatch terminal 10 is specifically used to compare the currently collected vital sign data with the contraindication threshold of the drug in real time. If the currently collected vital sign data exceeds the contraindication threshold, a local risk warning is triggered. During the preset drug efficacy monitoring period after medication, the smartwatch terminal 10 is specifically used to compare the changing trend of vital sign data with the drug efficacy improvement threshold. If the changing trend of vital sign data does not reach the efficacy improvement threshold, an abnormal efficacy warning is triggered and the medication behavior is reconfirmed through a pop-up window.
[0028] Specifically, during the medication window, the smartwatch 10 compares heart rate and exercise data with the contraindication thresholds for the medication in real time. If the thresholds are exceeded, a high-risk medication scenario is triggered locally, triggering a vibration pop-up alert. This comparison process can run independently of the phone. After normal medication administration, the smartwatch 10 continuously monitors vital signs such as blood pressure and heart rate within a preset medication efficacy monitoring period. If the vital signs do not reach the threshold for improving medication efficacy, an abnormal medication efficacy alert is triggered, prompting a second confirmation of medication administration via a pop-up window.
[0029] See Figure 4As shown, when a risk warning is triggered, the smartwatch terminal 10 displays a tiered risk reminder page. Specifically, when a high-risk medication scenario is triggered (strenuous exercise during the medication window, heart rate exceeding the standard), a full-screen pop-up window, continuous watch vibration, and tiered ringtone reminder are displayed. The pop-up window shows the risk type, side effects, and immediate rest suggestions. Users can turn off the reminder and view detailed drug contraindications. After the reminder is turned off, only the pop-up window is hidden, and vital signs are continuously monitored in the background. At the same time, the record of this risk event is automatically synchronized to the medication data for the day and included in the risk statistics. When the cumulative number of risk events reaches a set threshold, the mobile APP terminal 20 pushes a health check reminder.
[0030] See Figure 5 As shown, users can access the main drug category page by clicking the "Drug Management" icon on the medication homepage. The main drug category page displays four main drug category entries: Western medicines for chronic diseases, traditional Chinese medicines, dietary supplements, and emergency medications. Clicking on the corresponding category will take you to a list of all drugs in that category.
[0031] See Figure 6 As shown, clicking the drug category entry will take you to the corresponding drug category details page. For drugs not selected in the list, clicking will take you to the drug customization settings page, where you can add them to your frequently used list on the homepage. For drugs already selected, clicking to deselect them will remove them from the medication homepage, saving them only in the category library. Each drug entry includes basic matching physical signs and contraindicated exercise types for easy user identification.
[0032] Furthermore, the smartwatch terminal 10 also includes a drug parameter setting module, which is used to configure the user's medication time, dosage, precautions, as well as the medication window period, contraindication threshold, efficacy monitoring duration, efficacy threshold, and risk warning parameters for each drug.
[0033] See Figure 7 As shown, clicking on a drug item in the list will take you to the drug parameter settings page. This page allows users to set the medication time, dosage, and precautions; set the drug efficacy monitoring duration (range 0.5H-24H); set a ringtone (supports selection of the watch's built-in ringtone, with volume matching the watch's system volume; clicking the ringtone allows for preview playback); set vibration alerts (vibration is enabled by default for risk warnings, with intensity following system levels (strong / weak / none); set a drug icon; configure drug efficacy thresholds (for drugs for chronic diseases such as hypertension and hypoglycemia, blood pressure and heart rate safety improvement thresholds can be set for subsequent efficacy verification); view medication precautions; select to discontinue or delete the current drug; settings take effect immediately upon returning: drugs not added to the homepage are automatically added to the frequently used list; existing drug parameters are saved and synchronized to the app's cloud.
[0034] In practice, swiping left on the main watch face of the smartwatch terminal 10 enters the first-level shortcut page. If there are no medication records for the day, only the "Smart Medication" icon is displayed. (See [link]). Figure 8 As shown. Clicking the icon will take you directly to the medication function homepage, where you can quickly create new medications and set medication reminders.
[0035] See Figure 9 As shown, when there is a completed medication record for the day, the first-level page displays the "Today's Medication Usage" statistics panel. In this embodiment of the invention, only medication monitoring data that is completed naturally (time ends normally, no manual early closure, no system shutdown interruption) is counted; if the alarm is manually canceled or the medication is stopped midway, the monitored data is not included in the duration statistics; the statistics for the day are automatically cleared and reset at 0:00 every day; the statistics panel is sorted by medication administration time, displaying the monitoring status of the medication, administration time, dosage, and precautions; clicking on the corresponding category name will jump to the details page for that category of medication for the day.
[0036] See Figure 10 As shown, clicking the category name on the primary page will take you to the daily details page for that specific drug category. The daily details page for each drug category displays a single medication record, including: drug icon, monitoring duration, medication time; current vital signs: average heart rate, blood pressure, body temperature, and activity level; times when the watch was not worn are uniformly displayed as "--"; the efficacy verification results are displayed, including: comparison with preset lightweight drug thresholds, labeled with efficacy judgment tags such as "normal / blood pressure not reduced / abnormal heart rate"; multiple records are sorted by medication time.
[0037] The mobile app terminal 20 is used to receive and synchronize medication records, risk events, and vital sign data uploaded by the smartwatch terminal 10. For specific implementation details, please refer to... Figure 11 As shown, after the mobile phone is connected to the smartwatch terminal 10 via Bluetooth, select "Smart Medication Monitoring" in the APP device navigation bar to enter the main page of drug categories; after entering the category details page, you can swipe right on the item to delete a custom drug.
[0038] The mobile APP terminal 20 and the smartwatch terminal 10 synchronize information such as drug library, medication settings, daily medication data, and risk event records in real time. After removing a drug, the smartwatch terminal 10 simultaneously clears all local configurations and historical records of that drug. The mobile APP terminal 20 supports viewing all historical medication cycle reports and AI drug interaction overview.
[0039] See Figure 12As shown, clicking "Add" in the upper right corner of the category details page allows you to add a custom drug entry. This includes: custom drug name (maximum 7 Chinese characters, exceeding which will be truncated and hidden); parameter configuration items: medication monitoring duration, risk ringtone, exclusive icon, vibration switch, drug efficacy threshold, and whether to add immediately to the watch's home screen; ringtones can be imported from your phone's local audio, and imported ringtones are compatible with all drug categories; after clicking save, newly added drugs are selected by default, sorted to the end of the category, and automatically synced to the smartwatch's local storage.
[0040] The cloud-based AI analysis platform 30 is used to store a pharmaceutical knowledge base and perform drug interaction simulations based on the pharmaceutical knowledge base.
[0041] In one implementation, the cloud-based AI analysis platform 30 is specifically used to retrieve the medical knowledge base to perform multi-drug combination and drug-food interaction simulations based on all the medications and daily dietary records entered by the user, output graded and visualized risk warnings, and generate periodic medication safety reports.
[0042] In practice, a clinical-grade database is used as a foundation to obtain clinically validated drug-drug interaction pairs and their severity classifications. Simultaneously, a food-drug interaction database is accessed to obtain records of interactions between food / herbs and drugs, with each entry labeled with its effect direction (positive, negative, ineffective, harmful, possible). Furthermore, dynamic pharmacovigilance signals are obtained based on revisions to drug instructions (such as the addition of a black box warning for hemolytic anemia to carbamide peroxide) and pharmacovigilance bulletins.
[0043] During the simulation, the input layer is the user state vector. Specifically, the system collects not only a list of drug names, but also constructs a multi-dimensional state: the dosage, route of administration, and timing of administration for each drug; the composition of the daily diet and cooking methods (raw / cooked / fermented); and the user's variable factors, including age, liver and kidney function markers, and known metabolic enzyme polymorphisms.
[0044] The extrapolation layer employs three-tiered correlation analysis: First-tier correlation (direct pair): known interactions between drug A and drug B, and between drug A and food X. Second-tier correlation (through a medium): no direct interaction is recorded between drug A and drug B, but they both act on the same metabolic enzyme or transporter, and dietary component C happens to regulate this target. The system needs to identify these implicit competitive relationships. For example, when two drugs, both metabolized by CYP3A4, are taken with grapefruit juice, the risk is not simply additive, but nonlinearly amplified by enzyme saturation kinetics. Third-tier correlation (system emergence): the overall shift of the pharmacological system under the combined effects of multiple drugs and foods. This type of risk cannot be attributed to any single pair, but is a disruption of systemic homeostasis. A typical scenario is the cumulative effect of multiple mild anticholinergic loads, where the individual anticholinergic effects of each drug are not significant, but may trigger a threshold when combined with dietary factors in elderly patients. Each interaction pair outputs a risk interval estimate (e.g., moderate risk, confidence interval 0.45–0.62), and labels the dominant source of evidence driving the estimate.
[0045] In one implementation, see Figure 13 As shown, the mobile app terminal 20 includes a dedicated AI-powered drug interaction page. After the user enters all currently used medications and daily dietary records, the cloud-based AI analysis platform 30 automatically compares them with the cloud-based pharmaceutical database and displays the risks in a three-level visual representation: contraindicated combined use / interval dosing / minor impact on efficacy, distinguished by corresponding UI color blocks; the page displays optimized solutions, including: medication interval duration, a list of prohibited foods, and suggestions for alternative medications; risk records are stored long-term, automatically generating a monthly medication safety report (see...). Figure 14 (As shown).
[0046] The cloud-based AI analytics platform 30 is also used to generate personalized optimization plans based on users' historical heart rate and sleep data. These personalized optimization plans include: recommending alternative medications, suggesting adjustments to medication timing, and providing guidance on rest and recuperation.
[0047] In practice, the smartwatch terminal 10 continuously collects heart rate data, including resting heart rate, heart rate variability, and exercise heart rate zones, as well as sleep data, including sleep onset time, deep sleep duration, light sleep duration, REM sleep percentage, number of nighttime awakenings, and sleep efficiency. Simultaneously, based on indicators such as current heart rate, heart rate variability, and sleep debt, the user's status is categorized into several types, such as: well recovered, mild fatigue, moderate fatigue, severe fatigue, stress state, and sleep deprivation.
[0048] Secondly, by combining the pharmacokinetic characteristics of the drug taken by the user (onset time, half-life, time to peak concentration, metabolic pathway), an effect time window of the drug in the body is established. This effect time window is then matched with the user's daily heart rate and sleep rhythm to identify whether the peak drug effect conflicts with the user's physiological trough / peak. For example, if a drug reaches its peak at night and may cause increased heart rate or insomnia, while the user's heart rate should typically decrease at night, then the current time of medication may be unfavorable.
[0049] Next, a predictive model is trained using historical data. The inputs are recent heart rate, sleep, activity, and medication records. The outputs are: the probability of adverse reactions occurring in the future during the current medication period; whether the drug's efficacy might be reduced due to circadian rhythms during the current medication period; and the trends in fatigue recovery speed and sleep quality under the current rest and recuperation plan. The prediction results are used to generate candidate solutions for adjustment recommendations.
[0050] Furthermore, based on the drug type and the user's daily routine, multiple candidate medication time points are generated within a reasonable range. These candidate time points must meet basic medical constraints, such as intervals with meals, intervals with other medications, and daily frequency limits. For each candidate time period, the superposition effect of the drug effect curve with the user's typical heart rate and sleep rhythm is simulated after medication administration. The scoring dimensions include: maximization of therapeutic efficacy, minimization of adverse reaction risk, degree of interference with sleep structure, and user compliance (ease of adherence). The time period with the highest overall score is selected as the recommended adjustment plan.
[0051] After determining the candidate time slots, heart rate, sleep, and subjective feedback are continuously monitored after adjusting the medication time to observe whether the expected improvement is achieved. If there is no improvement for several consecutive days or discomfort occurs, the process is reverted or a second-best candidate option is tried. The actual effect after each adjustment is fed back into the model to update the user's response characteristics to medication time slot adjustments. As data accumulates, the model's judgment on when it is most suitable for the user to take medication becomes increasingly accurate. Ultimately, a personalized medication time recommendation is formed, which is dynamically fine-tuned according to changes in season, work intensity, and health status.
[0052] Finally, based on sleep debt, heart rate variability trends, and recent activity load, it is determined whether the user is currently in a state of "needing active recovery" or "able to withstand a certain workload." Simultaneously, a rest strategy library is established, containing various validated recovery methods, such as: short naps (20 or 90 minutes), deep breathing / meditation sessions; low-intensity walks; going to bed earlier; reducing caffeine intake; and adjusting work rhythm (such as variations of the Pomodoro Technique). Based on the user's current state and available time, matching strategies are selected from the library and embedded into the user's schedule for the current day or the following day, forming specific suggestions. For example: schedule a 20-minute nap from 13:00 to 13:20 today, because you did not get enough deep sleep last night and your resting heart rate is high this morning. It should be noted that all AI suggestions must be within medical safety limits and must not suggest changes to medication times beyond those permitted by the drug instructions or doctor's orders. Adjustments to medication times and rest behavior guidelines are only suggestions and must be confirmed by a doctor.
[0053] The AI-powered intelligent medication risk monitoring system based on wearable device vital sign data collection provided in this invention collects real-time vital sign data and activity status of users through a smartwatch terminal and compares it with pre-set lightweight drug thresholds to identify risk events. Simultaneously, through a cloud-based AI analysis platform that performs drug interaction simulations based on a medical knowledge base, it can intercept health risks caused by factors such as exercise and dietary changes after medication in real time, reducing the probability of adverse drug reactions and improving medication safety. Furthermore, the mobile app terminal can receive and synchronize medication records, risk events, and vital sign data uploaded from the smartwatch terminal, thereby achieving full-process safety monitoring of medication use.
[0054] See Figure 15 As shown, this invention is divided into three layers: a hardware layer for collecting vital signs on the watch, a local real-time computing layer on the watch, and an APP / cloud AI analysis and storage layer, forming a closed loop through end-to-end data interconnection. 1. Hardware layer for watch vital sign data collection: The watch has a built-in heart rate sensor, blood pressure monitoring module, motion posture sensor, and sleep monitoring module, which collects the user's vital signs and exercise data around the clock and synchronizes it to the watch's local storage via Bluetooth Low Energy.
[0055] 2. Watch Local Real-Time Computing Layer (1) Drug side effect linkage risk control logic: local lightweight drug threshold library, real-time comparison of heart rate and exercise intensity during the medication window period, and direct triggering of vibration pop-up warning when the threshold is exceeded. It can run independently without a mobile phone. (2) Drug efficacy and medication verification logic: After normal medication, blood pressure / heart rate is continuously monitored during the preset drug efficacy cycle. If the vital signs do not reach the improvement threshold, an abnormal drug efficacy warning is triggered, and a pop-up window confirms the medication behavior for the second time. (3) Multi-drug parallel timing logic: Supports simultaneous background monitoring of multiple drugs, independently recording their respective vital signs data without interference.
[0056] 3. APP cloud-based AI analysis layer (1) AI drug-food and drug interaction simulation: Based on a complete cloud-based medical knowledge base, batch analysis of the risks of multi-drug combination and dietary pairing, and output of graded visual prompts; (2) Big data management of medication cycle: Automatically collect daily / weekly / monthly medication data, risk triggers, and efficacy target data to generate a complete course review report; (3) Iterative personalized medication plan: Based on long-term heart rate and sleep big data, AI dynamically adjusts the optimal medication time and production rest suggestions.
[0057] The system provided in the embodiments of the present invention has the following technical effects: (1) Improve medication safety: Real-time interception of health risks caused by exercise and diet after taking medication, significantly reducing the probability of adverse drug reactions; (2) Solve the problem of missed doses and false medication for chronic diseases: The dual verification mechanism actively reminds patients of abnormal conditions such as missed doses and abnormal drug efficacy, thereby ensuring the long-term therapeutic effect of medication; (3) Personalized scientific medication: The medication plan is dynamically adjusted based on the individual's long-term heart rate and sleep data, breaking away from the uniform and fixed time reminder mode; (4) Full-cycle traceability of medication data: Automatically retain all medication, risk and vital sign records to provide users and medical staff with complete medication reference; (5) No restrictions on usage scenarios: The watch supports complete monitoring and early warning functions locally, without the need for a continuous Bluetooth connection with a mobile phone, and can be used independently outdoors or at home.
[0058] Regarding the AI-based intelligent medication risk monitoring system based on intelligent wearable vital sign collection provided in the foregoing embodiments, this invention also provides an AI-based intelligent medication risk monitoring method based on intelligent wearable vital sign collection. This method is applied to the AI-based intelligent medication risk monitoring system provided in any of the above embodiments. See [link to relevant documentation]. Figure 16 The diagram shown illustrates an AI-powered intelligent medication risk monitoring method based on wearable device-based vital sign data collection. The method mainly includes the following steps S1601 to S1603: Step S1601: Collect the user's real-time vital signs data and movement status through the smartwatch terminal, compare the real-time vital signs data and movement status with the pre-set lightweight drug threshold, and identify risk events based on the comparison results.
[0059] Step S1602: Receive and synchronize medication records, risk events, and vital signs data uploaded by the smartwatch terminal via the mobile APP terminal.
[0060] Step S1603: Store the medical knowledge base through the cloud AI analysis platform and perform drug interaction simulation based on the medical knowledge base.
[0061] The AI-based intelligent medication risk monitoring method based on wearable device vital sign data collection provided in this invention collects real-time vital sign data and activity status of users through a smartwatch terminal and compares it with pre-set lightweight drug thresholds to identify risk events. Simultaneously, a cloud-based AI analysis platform performs drug interaction simulations based on a medical knowledge base, enabling real-time interception of health risks caused by factors such as exercise and dietary changes after medication, reducing the probability of adverse drug reactions and improving medication safety. Furthermore, a mobile app terminal can receive and synchronize medication records, risk events, and vital sign data uploaded from the smartwatch terminal, thereby achieving full-process safety monitoring of medication use.
[0062] It should be noted that the method provided in this embodiment of the invention has the same implementation principle and technical effects as the aforementioned system embodiment. For the sake of brevity, any parts not mentioned in the method embodiment can be referred to the corresponding content in the aforementioned system embodiment. The specific numerical values provided in this embodiment are merely exemplary and are not intended to limit the scope of the invention.
[0063] This invention also provides an electronic device, specifically, the electronic device includes a processor and a storage device; the storage device stores a computer program, and the computer program, when run by the processor, executes the method described in any of the above embodiments.
[0064] Figure 17 This is a schematic diagram of the structure of an electronic device provided in an embodiment of the present invention. The electronic device 100 includes: a processor 170, a memory 171, a bus 172 and a communication interface 173. The processor 170, the communication interface 173 and the memory 171 are connected through the bus 172. The processor 170 is used to execute executable modules, such as computer programs, stored in the memory 171.
[0065] The memory 171 may include high-speed random access memory (RAM) or non-volatile memory, such as at least one disk storage device. Communication between this system network element and at least one other network element is achieved through at least one communication interface 173 (which can be wired or wireless), such as the Internet, wide area network, local area network, metropolitan area network, etc.
[0066] Bus 172 can be an ISA bus, PCI bus, or EISA bus, etc. The bus can be divided into address bus, data bus, control bus, etc. For ease of representation, Figure 17 The symbol is represented by a single double-headed arrow, but this does not mean that there is only one bus or one type of bus.
[0067] The memory 171 is used to store programs. After receiving an execution instruction, the processor 170 executes the program. The method executed by the device for defining the flow process disclosed in any of the foregoing embodiments of the present invention can be applied to the processor 170 or implemented by the processor 170.
[0068] Processor 170 may be an integrated circuit chip with signal processing capabilities. In implementation, each step of the above method can be completed by the integrated logic circuitry in the hardware of processor 170 or by instructions in software form. Processor 170 can be a general-purpose processor, including a Central Processing Unit (CPU), a Network Processor (NP), etc.; it can also be a Digital Signal Processor (DSP), an Application Specific Integrated Circuit (ASIC), a Field-Programmable Gate Array (FPGA), or other programmable logic devices, discrete gate or transistor logic devices, or discrete hardware components. It can implement or execute the methods, steps, and logic block diagrams disclosed in the embodiments of this invention. The general-purpose processor can be a microprocessor or any conventional processor. The steps of the methods disclosed in the embodiments of this invention can be directly manifested as execution by a hardware decoding processor, or execution by a combination of hardware and software modules in the decoding processor. The software module can reside in a mature storage medium in the art, such as random access memory, flash memory, read-only memory, programmable read-only memory, electrically erasable programmable memory, or registers. This storage medium is located in memory 171, and processor 170 reads the information in memory 171 and, in conjunction with its hardware, completes the steps of the above method.
[0069] The computer program product of the readable storage medium provided in the embodiments of the present invention includes a computer-readable storage medium storing program code. The instructions included in the program code can be used to execute the methods described in the foregoing method embodiments. For specific implementation, please refer to the foregoing method embodiments, which will not be repeated here.
[0070] If the aforementioned functions are implemented as software functional units and sold or used as independent products, they can be stored in a computer-readable storage medium. Based on this understanding, the technical solution of this invention, essentially, or the part that contributes to the prior art, or a portion of the technical solution, can be embodied in the form of a software product. This computer software product is stored in a storage medium and includes several instructions to cause a computer device (which may be a personal computer, server, or network device, etc.) to execute all or part of the steps of the methods described in the various embodiments of this invention. The aforementioned storage medium includes various media capable of storing program code, such as USB flash drives, portable hard drives, read-only memory (ROM), random access memory (RAM), magnetic disks, or optical disks.
[0071] Finally, it should be noted that the above-described embodiments are merely specific implementations of the present invention, used to illustrate the technical solutions of the present invention, and not to limit it. The scope of protection of the present invention is not limited thereto. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that any person skilled in the art can still modify or easily conceive of changes to the technical solutions described in the foregoing embodiments within the technical scope disclosed in the present invention, or make equivalent substitutions for some of the technical features; and these modifications, changes, or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention, and should all be covered within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.
Claims
1. An AI-powered intelligent medication risk monitoring system based on smart wearable device vital sign collection, characterized in that, include: The smartwatch terminal is used to collect the user's real-time vital signs data and movement status, and compare the real-time vital signs data and movement status with a pre-set lightweight drug threshold, and identify risk events based on the comparison results; A mobile APP terminal is used to receive and synchronize the medication records, risk events, and vital sign data uploaded by the smartwatch terminal; A cloud-based AI analysis platform is used to store a pharmaceutical knowledge base and perform drug interaction simulations based on the pharmaceutical knowledge base.
2. The system according to claim 1, characterized in that, The smartwatch terminal has a built-in lightweight drug threshold library, which includes: the medication window period and lightweight drug threshold for each drug; wherein, the lightweight drug threshold includes: contraindication sign threshold and efficacy improvement threshold; The smartwatch terminal is used for parallel background monitoring of multiple drugs. The medication window period, preset efficacy monitoring duration after medication, contraindication threshold, and efficacy improvement threshold of each drug are configured independently and do not interfere with each other.
3. The system according to claim 2, characterized in that, During the medication window period, the smartwatch terminal is used to compare the currently collected vital sign data with the contraindication threshold of the drug in real time. If the currently collected vital sign data exceeds the contraindication threshold, a local risk warning is triggered. Within a preset duration of drug efficacy monitoring after medication, the smartwatch terminal compares the trend of changes in the vital signs data with the drug efficacy improvement threshold. If the trend of changes in the vital signs data does not reach the efficacy improvement threshold, an abnormal efficacy warning is triggered, and the medication behavior is reconfirmed via a pop-up window.
4. The system according to claim 1, characterized in that, The cloud-based AI analysis platform is specifically used to retrieve medical knowledge bases based on all medications used and daily dietary records entered by the user, to perform multi-drug combination and drug-food interaction simulations, output graded and visualized risk alerts, and generate periodic medication safety reports.
5. The system according to claim 1, characterized in that, The smartwatch terminal includes: a heart rate sensor, a blood pressure monitoring module, a motion posture sensor, a sleep monitoring module, and a local storage unit; The heart rate sensor, the blood pressure monitoring module, the motion posture sensor, and the sleep monitoring module are used to collect the user's heart rate, blood pressure, exercise status, and sleep data, respectively, and cache the collected data to the local storage unit.
6. The system according to claim 5, characterized in that, The cloud-based AI analytics platform is also used to generate personalized optimization plans based on users' historical heart rate and sleep data. These personalized optimization plans include recommendations for alternative medications, suggestions for adjusting medication timing, and guidelines for rest and recuperation.
7. The system according to claim 1, characterized in that, The smartwatch terminal includes a drug parameter setting module, used to configure the user's medication time, dosage, precautions, as well as the medication window period, contraindication threshold, efficacy monitoring duration, efficacy threshold, and risk warning parameters for each drug.
8. An AI-powered intelligent medication risk monitoring method based on smart wearable device vital sign collection, characterized in that, The method, applied to the AI-powered intelligent medication risk monitoring system according to any one of claims 1-7, comprises: The system collects real-time vital signs and movement status of users through a smartwatch terminal, compares the real-time vital signs and movement status with a pre-set lightweight drug threshold, and identifies risk events based on the comparison results. The medication records, risk events, and vital sign data uploaded by the smartwatch terminal are received and synchronized through a mobile APP terminal. A medical knowledge base is stored through a cloud-based AI analysis platform, and drug interaction simulations are performed based on this medical knowledge base.
9. An electronic device, characterized in that, The method includes a processor and a memory, the memory storing computer-executable instructions that can be executed by the processor, the processor executing the computer-executable instructions to implement the steps of the method of claim 8.
10. A computer-readable storage medium storing a computer program thereon, characterized in that, The computer program is executed by the processor to perform the steps of the method described in claim 8.
